Tenaya Therapeutics Statistics
Total Valuation
TNYA has a market cap or net worth of $73.53 million. The enterprise value is $25.10 million.
Important Dates
The next estimated earnings date is Tuesday, May 13, 2025, after market close.
| Earnings Date | May 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TNYA has 161.54 million shares outstanding. The number of shares has increased by 14.96% in one year.
| Current Share Class | 161.54M |
| Shares Outstanding | 161.54M |
| Shares Change (YoY) | +14.96% |
| Shares Change (QoQ) | +0.28% |
| Owned by Insiders (%) | 0.62% |
| Owned by Institutions (%) | 20.71% |
| Float | 101.82M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.42 |
| P/TBV Ratio | 0.79 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.22, with a Debt / Equity ratio of 0.15.
| Current Ratio | 4.22 |
| Quick Ratio | 3.85 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -95.69% and return on invested capital (ROIC) is -56.11%.
| Return on Equity (ROE) | -95.69% |
| Return on Assets (ROA) | -49.90% |
| Return on Invested Capital (ROIC) | -56.11% |
| Return on Capital Employed (ROCE) | -111.53% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.15M |
| Employee Count | 97 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -89.72% in the last 52 weeks. The beta is 2.99, so TNYA's price volatility has been higher than the market average.
| Beta (5Y) | 2.99 |
| 52-Week Price Change | -89.72% |
| 50-Day Moving Average | 0.69 |
| 200-Day Moving Average | 1.89 |
| Relative Strength Index (RSI) | 36.96 |
| Average Volume (20 Days) | 2,413,746 |
Short Selling Information
The latest short interest is 10.82 million, so 6.70% of the outstanding shares have been sold short.
| Short Interest | 10.82M |
| Short Previous Month | 11.22M |
| Short % of Shares Out | 6.70% |
| Short % of Float | 10.63% |
| Short Ratio (days to cover) | 1.88 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -115.95M |
| Pretax Income | n/a |
| Net Income | -111.13M |
| EBITDA | -107.48M |
| EBIT | -115.95M |
| Earnings Per Share (EPS) | -$1.31 |
Full Income StatementBalance Sheet
The company has $61.45 million in cash and $13.61 million in debt, giving a net cash position of $47.84 million or $0.30 per share.
| Cash & Cash Equivalents | 61.45M |
| Total Debt | 13.61M |
| Net Cash | 47.84M |
| Net Cash Per Share | $0.30 |
| Equity (Book Value) | 92.85M |
| Book Value Per Share | 1.07 |
| Working Capital | 51.40M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$90.50 million and capital expenditures -$1.03 million, giving a free cash flow of -$91.53 million.
| Operating Cash Flow | -90.50M |
| Capital Expenditures | -1.03M |
| Free Cash Flow | -91.53M |
| FCF Per Share | -$0.57 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |